The evidence base for pentadeca arginate is thinner than the evidence base for BPC-157. A targeted PubMed search found no peer-reviewed PDA-specific studies, so claims about improved stability, potency, or tissue penetration remain marketing hypotheses rather than published findings.
Physicians may submit patient-specific prescription requests for pentadeca arginate for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, supported by patient-specific documentation, and approved by the dispensing pharmacy. Availability is determined case by case. This is not a consumer access promise; it is a clinical, sourcing, formulation, and regulatory review process. This ingredient is part of an evolving FDA review process for peptide-related bulk substances, with review anchored by the closely related BPC-157 record.
The patient-specific pharmacy route is especially important when the published PDA record is nearly absent. It keeps a marketing claim about an arginate salt from becoming a consumer product claim without prescriber documentation and pharmacist review.
In brief
Pentadeca Arginate (PDA) Explained
Pentadeca Arginate, or PDA, is a peptide that is sold and marketed as an upgraded version of an older research peptide called BPC-157 1. PDA is the same 15-amino-acid sequence as BPC-157, formulated as an arginate (arginine) salt that the marketers claim makes it more stable and more available to tissues. Most of those claims come from manufacturer materials, not from published research.
As of May 2026, there is essentially no peer-reviewed human or animal research on PDA itself in the medical literature. Almost all of the published science on this class of peptide is on BPC-157, and that research is itself almost entirely in rodents, mostly from a single research group. No PDA product has FDA approval for any condition.
Pentadeca arginate has no FDA approval in the United States. This ingredient is part of an evolving FDA review process. Physicians may submit patient-specific prescription requests for pharmacy review. Availability is determined case by case, and availability may change after FDA review, PCAC discussion, final agency action, or state-board guidance.
At a glance
Quick Facts About Pentadeca Arginate (PDA)
Category
Investigational pentadecapeptide arginate salt; marketed as a BPC-157 analog
Active ingredient
A 15-amino-acid peptide (sequence as marketed: GEPPPGKPADDAGLV) formulated as an arginate salt purported to improve solubility, stability, and tissue penetration relative to BPC-157 acetate
FDA-approved branded forms
None. There is no FDA-approved product containing pentadeca arginate for any indication.
Route
Subcutaneous, intramuscular, or oral as marketed in research-peptide channels; no labeled or compendial route
Evidence posture
A PubMed search for 'pentadeca arginate' on 2026-05-11 returned zero results. Published peer-reviewed human or animal data for PDA itself are effectively absent; marketing claims rely on extrapolation from the BPC-157 preclinical literature and from unpublished manufacturer-sourced material.
FDA-approval status
Category 2, evolving FDA review process. Valid patient-specific prescription required; supporting clinical rationale may be requested.
Compounded under
Physicians may submit patient-specific prescription requests for pharmacy review. Availability is determined case by case.
Important compounding caution
Physicians may submit patient-specific prescription requests for pharmacy review. Availability is determined case by case.
Prescription review
Patient-Specific Prescription Only
Physicians may submit patient-specific prescription requests for Pentadeca Arginate (PDA) for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Pentadeca Arginate (PDA)?
Pentadeca Arginate (PDA) is, as marketed, a 15-amino-acid peptide identical in primary sequence to Body Protection Compound 157 (BPC-157), itself derived from a fragment of a human gastric juice protein originally characterized by Sikiric and colleagues at the University of Zagreb in the 1990s 5. PDA is differentiated from BPC-157 acetate by its counter-ion: arginate (an arginine salt) rather than acetate. The arginate counter-ion is the basis for marketing claims of improved aqueous solubility, longer shelf-life, and better tissue distribution.
There is no FDA-approved product containing PDA for any indication. There is no USP monograph. PDA is not listed on the FDA 503A or 503B Category 1 bulks lists, and by sequence-and-class analogy to BPC-157 it falls within the broader category of investigational pentadecapeptides under FDA scrutiny 2.
Distinct from the underlying BPC-157 literature, a PubMed search for 'pentadeca arginate' on 2026-05-11 returned zero results 1. PDA is therefore best characterized as a marketing-stage molecule: claimed properties have not been published in peer-reviewed PubMed-indexed journals, and any inferences about its behavior in humans are extrapolations from the BPC-157 rodent literature plus manufacturer-supplied material that is not independently reproducible.
How it works
How Pentadeca Arginate (PDA) Works
Class
Pentadecapeptide arginate
First studied
Recent (2020s)
Current status
Category 2, evolving FDA review process
Compounding category
Patient-specific 503A on physician request, pending broader FDA review
No PDA-specific mechanism-of-action data have been published in PubMed-indexed journals as of 2026-05-11 1. The mechanistic framework cited by PDA marketers is borrowed directly from the BPC-157 literature.
In rodent BPC-157 work, the proposed mechanism centers on modulation of the nitric-oxide (NO) system, upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), and effects on angiogenesis and collateral circulation that the authors frame as 'cytoprotection' against gastrointestinal, vascular, and musculoskeletal injury 81416. Reported downstream effects in rat models include accelerated tendon-to-bone healing, ligament healing, muscle and myotendinous-junction repair, mucosal healing in colitis and anastomotic injury models, and counteraction of occlusion-like vascular failure 7910.
These mechanism claims have not been independently replicated outside the originating laboratory at the level of detail or breadth reported, and they have not been demonstrated for PDA specifically. The arginate-counter-ion claim, that salt form alters tissue distribution or potency, is a pharmaceutical hypothesis that has not been tested for PDA in any peer-reviewed publication identified in PubMed 11312.
Research history
Pentadeca Arginate (PDA) Research History
BPC-157, the parent compound from which PDA is derived, was characterized in the 1990s by Sikiric and colleagues as a 15-amino-acid fragment of a larger gastric juice protein, initially studied in rodent gastric-ulcer and cytoprotection models 5. A synthetic version designated PL 14736 advanced into early clinical investigation for ulcerative colitis under the development name later associated with BPC-157; the Sikiric group reviewed that program in 2012 6. The substance never reached an FDA-approved product 21.
Through the 2010s and 2020s the BPC-157 preclinical literature expanded substantially in rodent injury models, including ligament healing 7, myotendinous-junction repair 9, striated and smooth muscle effects 10, intestinal anastomosis 13, duodenocolic fistula 12, and a multi-decade arc of gastrointestinal cytoprotection studies summarized in narrative reviews by the originating group 81411. Independent narrative reviews and systematic reviews in orthopaedic and sports-medicine literature uniformly characterize the human evidence base as sparse and the use as off-label and investigational 191720.
PDA emerged as a marketing category in the early 2020s, positioned as a 'next-generation' arginate-salt form of BPC-157. A direct PubMed search for 'pentadeca arginate' on 2026-05-11 returned zero results 1. No clinical trials of PDA were identified in PubMed; no pharmacokinetic, stability, or tissue-distribution studies were identified. The substance entered FDA regulatory awareness alongside other compounded peptides under the interim 503A bulks framework 2.
Timeline
Pentadeca Arginate (PDA) Timeline
1990sSikiric and colleagues at the University of Zagreb characterize BPC-157 as a 15-amino-acid fragment of a human gastric juice protein and report cytoprotection effects in rodent ulcer models 5
2010Cerovecki et al 7. (J Orthop Res), BPC-157 (also referenced as PL 14736) reportedly accelerates ligament healing in a rat medial collateral ligament transection model
2012Sikiric et al 6. (Curr Med Chem) review the BPC-157 / PL 14736 development program for ulcerative colitis
2021Seiwerth et al 8. (Front Pharmacol) publish a narrative review of BPC-157 wound-healing literature centered on nitric-oxide-system and VEGFR2 mechanisms
2021Japjec et al 9. (Biomedicines) report a myotendinous-junction injury study in rats
2022Staresinic et al 10. (Biomedicines), review of BPC-157 effects on striated, smooth, and heart muscle in rodent models
2023FDA classifies BPC-157 as Category 2 under the interim 503A bulks framework, citing immunogenicity concerns, manufacturing impurity risk, and absence of human safety data 2
2023Sikiric et al 11. (Pharmaceuticals) historical review of cytoprotection literature from cysteamine-duodenal-ulcer models through dopamine-stomach work
2024Sikiric et al 14. (Inflammopharmacology) consolidate occlusion-like vascular-syndrome cytoprotection studies
2024Bajramagic et al 13. (Pharmaceuticals) review BPC-157 in rat intestinal anastomosis healing
2024Vukusic et al 12. (J Physiol Pharmacol) report duodenocolic fistula healing with BPC-157 in rats
2025Józwiak et al 15. (Pharmaceuticals) publish a literature-and-patent review of BPC-157 highlighting concentration of reports within a single research group
2025Sikiric et al 16. (Pharmaceuticals) publish a commentary responding to Józwiak, restating the nitric-oxide / angiogenesis mechanism framework
2025Whitehouse (Inflammopharmacology) commentary on the BPC-157 cytoprotection narrative and its translational limits 18
2025Vasireddi et al. (HSS J), systematic review of BPC-157 in orthopaedic sports medicine; McGuire et al 1719. (Curr Rev Musculoskelet Med) narrative review framing BPC-157 as 'regeneration or risk' given the human evidence gap
2026Mayfield et al 2021. (Am J Sports Med) injectable-peptide primer; Mendias and Awan (Sports Med) review of approved and unapproved peptide therapies for musculoskeletal injuries, both cite the unapproved status and limited human safety data for BPC-157-class peptides
2026PubMed search for 'pentadeca arginate' returns zero results, confirms that, as of the brief review date, no PDA-specific peer-reviewed literature is indexed 1
Marketed indications for PDA borrow directly from the BPC-157 rodent literature; no PDA-specific clinical or preclinical evidence is published in PubMed.
Marketing material positions PDA as supporting tendon, ligament, muscle, and gastrointestinal mucosal repair, citing BPC-157 rodent studies in ligament transection 7, myotendinous-junction injury 9, striated/smooth/heart muscle models 10, intestinal anastomosis 13, and duodenocolic fistula 12. Those studies are in rats, are concentrated in a single research group, and have not been replicated for PDA 21. Independent reviews characterize the underlying human evidence base as insufficient to support clinical practice outside investigational settings 191720.
Compounded use
Compounded Pentadeca Arginate (PDA) (503A)
Physicians may submit patient-specific prescription requests for pharmacy review. For pentadeca arginate, certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case and may depend on patient-specific documentation, ingredient status, source qualification, formulation feasibility, state requirements, and pharmacist judgment. The review starts with the evidence constraint: The evidence base for pentadeca arginate is thinner than the evidence base for BPC-157. A targeted PubMed search found no peer-reviewed PDA-specific studies, so claims about improved stability, potency, or tissue penetration remain marketing hypotheses rather than published findings.
This ingredient is part of an evolving FDA review process. RonanRx is monitoring FDA's PCAC process and any subsequent agency action. This ingredient is part of an evolving FDA review process for peptide-related bulk substances, with review anchored by the closely related BPC-157 record. Availability may change after FDA review, PCAC discussion, final agency action, or state-board guidance. For pentadeca arginate, RonanRx ties that monitoring to the evidence limits described above and to any patient-specific documentation submitted by the prescriber.
Valid patient-specific prescription required. Supporting clinical rationale may be requested. Compounded medications are not FDA-approved. No consumer self-ordering, no office stock, no bulk dispensing. Requests for pentadeca arginate are reviewed before any preparation is made or released. The patient-specific pharmacy route is especially important when the published PDA record is nearly absent. It keeps a marketing claim about an arginate salt from becoming a consumer product claim without prescriber documentation and pharmacist review.
Formulations and routes
Pentadeca Arginate (PDA) Formulations and Routes
Form
Concentration
Description
Sterile subcutaneous or intramuscular injection (research-peptide channel)
As marketed, typically 2, 10 mg lyophilized vials reconstituted with bacteriostatic water; doses cited in marketing material range widely without published support
PDA as sold in the research-peptide channel is supplied as a lyophilized powder for reconstitution. Identity, potency, sterility, and endotoxin testing standards in that channel are heterogeneous and are not equivalent to USP <797> sterile-compounding standards. RonanRx does not source or dispense from these channels.2
Routes used in published literature: subcutaneous, intramuscular, oral.
Dosing
Pentadeca Arginate (PDA) Dosing
Route
Population
Range
Duration
Study type
Not applicable
No published peer-reviewed dose-finding data for PDA in any population
No dose range is supported by peer-reviewed PubMed-indexed evidence; marketing-channel dose recommendations are not derived from controlled studies
There is no PubMed-indexed peer-reviewed dose-finding data for PDA in humans or in animal models as of 2026-05-11 1. Marketing-channel dose recommendations should not be treated as clinical guidance.
Even in the parent compound BPC-157, dose-finding data are limited to rodent injury models from a single research group, and translation to human dosing is not supported by published pharmacokinetic or pharmacodynamic studies in humans 81417. Independent reviews caution explicitly against extrapolation 192021.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Pentadeca Arginate (PDA) Safety
Safety overview
No human safety dataset for pentadeca arginate has been published in PubMed-indexed journals as of 2026-05-11 1. The FDA's Category 2 classification of the parent compound BPC-157 explicitly cites three safety domains, potential immunogenicity from peptide aggregation or impurities, manufacturing-related contaminant risk in non-cGMP supply chains, and the absence of controlled human safety data 221. None of those concerns has been resolved for PDA, and no peer-reviewed PDA-specific safety study addresses them.
The BPC-157 rodent literature reports a broadly favorable acute tolerability profile in rats at the doses used in those studies 814. That profile is not interchangeable with a human safety profile and does not transfer to PDA without independent characterization. Independent narrative and systematic reviews of BPC-157 in orthopaedic/sports-medicine populations consistently flag the absence of human safety data and the use of unregulated research-peptide supply as the dominant safety concerns clinicians and patients face in practice 191720.
Patients who have used PDA from research-peptide channels should be assessed clinically for injection-site reactions, hypersensitivity, and any unexpected events 19. There is no validated assay panel for PDA-specific monitoring.
Contraindications
Honest gap. No published contraindication framework for pentadeca arginate identified in PubMed-indexed journals or in FDA labeling. PDA is not an FDA-approved drug and has no Prescribing Information.
Searched: PubMed, FDA Drug Compounding (bulks lists) on 2026-05-11 · terms pentadeca arginate; pentadeca arginate contraindications; pentadeca arginate adverse.
Drug interactions
Honest gap. No published drug-interaction data for pentadeca arginate identified. The substance is not metabolized through any characterized pathway in humans because no human pharmacokinetic studies have been published.
Searched: PubMed, DailyMed on 2026-05-11 · terms pentadeca arginate drug interactions.
Adverse events
Honest gap. No peer-reviewed published adverse-event series for pentadeca arginate identified. The FDA Category 2 classification of the parent compound BPC-157 cites theoretical immunogenicity and manufacturing-impurity risks but does not enumerate a clinical adverse-event profile from controlled trials.
Searched: PubMed, FDA Adverse Event Reporting System (FAERS), limited public access on 2026-05-11 · terms pentadeca arginate adverse; pentadeca arginate AE.
Monitoring
Monitoring Pentadeca Arginate (PDA) Therapy
There is no validated monitoring framework for pentadeca arginate. No PubMed-indexed peer-reviewed publication has characterized the relevant safety laboratory or imaging follow-up for patients exposed to PDA 1. Clinicians evaluating patients who have self-administered PDA from research-peptide channels should perform a clinical assessment focused on injection-site reactions, hypersensitivity manifestations, and any unexpected systemic signs, and document the exposure in the medical record.
Special populations
Pentadeca Arginate (PDA) in Special Populations
Pregnancy
No published data on pentadeca arginate in pregnancy 1. PDA is not an FDA-approved product and there is no labeled pregnancy classification. Use in pregnancy is not supported by any peer-reviewed evidence.
Lactation
No data on the presence of pentadeca arginate in human milk or on its effects on the breastfed infant 1. There is no peer-reviewed publication addressing this population.
Pediatric
Safety and pharmacology in pediatric populations have not been studied. No peer-reviewed pediatric data exist 1.
Geriatric
No dedicated geriatric studies of pentadeca arginate have been published 1. The general clinician-facing reviews of BPC-157-class peptides flag the absence of any age-stratified human data 1917.
Renal impairment
No pharmacokinetic data in renal impairment. As a peptide, PDA would be expected to clear by proteolytic catabolism, but this has not been characterized for PDA in published peer-reviewed work 1.
Hepatic impairment
No pharmacokinetic data in hepatic impairment. No published characterization for PDA 1.
Evidence quality
Pentadeca Arginate (PDA) Evidence Quality
Evidence for pentadeca arginate itself is effectively absent from the peer-reviewed PubMed-indexed literature as of 2026-05-11 1. A targeted PubMed search returned zero results for the term 'pentadeca arginate'. There are no published pharmacokinetic, stability, sterility, mechanism, efficacy, or safety studies of PDA 21. There are no registered clinical trials. The substance is best characterized as a marketing-stage molecule whose claimed properties have not been independently demonstrated.
Evidence for the parent compound BPC-157 is broader but remains weak by clinical-trial standards 18. The corpus is concentrated in rodent injury models from a single research group (Sikiric and colleagues at the University of Zagreb), with a 2025 patent-and-literature review explicitly noting that concentration 15 and a 2025 commentary from the originating group restating its mechanism framework 16. Recent narrative and systematic reviews in independent orthopaedic and sports-medicine journals uniformly characterize the human evidence as insufficient to support clinical practice and frame BPC-157 use as off-label and investigational at best 191720.
By analogy and by direct review, PDA has not met a clear evidence threshold for broad 503A use. RonanRx documents the substance so physician-submitted requests can be evaluated against the absence of PDA-specific peer-reviewed characterization data, the BPC-157-related FDA review posture, and patient-specific rationale 23.
Systematic review of the BPC-157 literature for orthopaedic sports-medicine applications
—
—
Concludes that human evidence for BPC-157 is insufficient to support clinical use; the bulk of supporting data comes from rodent studies, and the regulatory status precludes routine compounding 17. PDA is not specifically addressed in PubMed-indexed work.
Narrative review of BPC-157 musculoskeletal-healing literature
—
—
Frames BPC-157 use as off-label and investigational; flags the absence of controlled human safety and efficacy data and the regulatory ambiguity for compounding 19
Catalogs the reported indications and mechanisms; explicitly notes the concentration of the literature within a single research group as a key limitation 15
Narrative review of BPC-157 wound-healing literature, primarily rodent models
—
—
Summarizes reported effects on angiogenesis, granulation tissue, and connective-tissue repair in rat models; mechanism centered on NO system and VEGFR2 8
Review of approved and unapproved peptide therapies for musculoskeletal injury
—
—
Classifies BPC-157 as unapproved with insufficient human safety and efficacy data; analog products including arginate-salt variants share the same evidence gap 21
Mechanism detail
Detailed Mechanism of Pentadeca Arginate (PDA)
BPC-157 has been reported in rodent studies to influence the nitric-oxide system, modulate angiogenesis via VEGFR2 signaling, and support epithelial and connective-tissue repair under stress conditions 814. A 2025 review/patent analysis by Józwiak et al. cataloged the breadth of reported mechanisms and explicitly noted that the corpus is dominated by a single research group and that independent replication remains limited 15. A 2025 commentary by Sikiric and colleagues, responding to that review, restated the mechanism framework centered on nitric-oxide and angiogenic effects 16.
For PDA specifically, no mechanistic study has been published in PubMed as of 2026-05-11 1. The marketing claim is that the arginate counter-ion enhances solubility, in-solution stability, and tissue delivery relative to BPC-157 acetate. Counter-ion choice can in principle affect aqueous solubility and dissolution rate of peptide salts, but for PDA there are no published stability-indicating analytical data, no published pharmacokinetic comparison versus BPC-157 acetate, and no published in vitro or in vivo data demonstrating improved tissue distribution. The mechanism narrative for PDA is therefore an extrapolation layered on top of an already extrapolated mechanism framework.
A clinical commentary by Whitehouse (2025) further emphasized that even the broad cytoprotection claims around BPC-157 rest on a narrow translational base 18. The cumulative caveat compounds for PDA: limited rodent data on the parent compound, no published data on the salt form, and no human trials of either form registered in PubMed.
No pentadeca arginate pharmacokinetic study has been published in PubMed-indexed journals as of 2026-05-11 1. There are no published data on absorption, distribution, metabolism, elimination, half-life, or bioavailability for PDA in any species or route. The marketing claim of improved tissue penetration via the arginate counter-ion is not supported by published comparative pharmacokinetic data.
For the parent compound BPC-157, the reported pharmacokinetic profile is limited to inferences from rodent activity studies and small-molecule peptide-class assumptions; no comprehensive validated human PK study is available in PubMed.
Pharmacodynamics
No pentadeca arginate pharmacodynamic study has been published in PubMed-indexed journals as of 2026-05-11 1. The pharmacodynamic claims attributed to PDA mirror those reported for BPC-157 in rodent models, modulation of the nitric-oxide system, angiogenesis effects via VEGFR2, and tissue-repair acceleration in injury models 814, but they have not been independently characterized for PDA.
Comparative formulations
Comparing Pentadeca Arginate (PDA) Formulations
There is no FDA-approved formulation of pentadeca arginate. Comparison to a reference product is not possible because no reference product exists. Marketing-channel PDA preparations vary in concentration, excipient profile, and reconstitution diluent; identity, potency, sterility, and endotoxin testing standards in those channels are heterogeneous and are not equivalent to USP <797> sterile-compounding standards 4.
Comparison to BPC-157 acetate, the parent compound, is similarly limited by the absence of head-to-head published comparative data 4. Claims that the arginate salt form is superior to the acetate form on stability, solubility, or tissue distribution have not been demonstrated in any peer-reviewed PubMed-indexed publication 1.
Storage
Pentadeca Arginate (PDA) Storage and Handling
No validated storage stability data have been published for pentadeca arginate. Marketing-channel product is typically supplied as a lyophilized powder for reconstitution with bacteriostatic water and refrigerated storage after reconstitution, but these recommendations are not supported by peer-reviewed stability-indicating analytical data 1. If RonanRx were ever to compound PDA following Category 1 status, storage and beyond-use dating would be governed by USP <797> and by validated stability data developed at the pharmacy 4.
RonanRx operations
Pentadeca Arginate (PDA) Compounding & Operations
503A compounding
Physicians may submit patient-specific prescription requests for pharmacy review. For pentadeca arginate, certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case and may depend on patient-specific documentation, ingredient status, source qualification, formulation feasibility, state requirements, and pharmacist judgment. The review starts with the evidence constraint: The evidence base for pentadeca arginate is thinner than the evidence base for BPC-157. A targeted PubMed search found no peer-reviewed PDA-specific studies, so claims about improved stability, potency, or tissue penetration remain marketing hypotheses rather than published findings.
This ingredient is part of an evolving FDA review process. RonanRx is monitoring FDA's PCAC process and any subsequent agency action. This ingredient is part of an evolving FDA review process for peptide-related bulk substances, with review anchored by the closely related BPC-157 record. Availability may change after FDA review, PCAC discussion, final agency action, or state-board guidance. For pentadeca arginate, RonanRx ties that monitoring to the evidence limits described above and to any patient-specific documentation submitted by the prescriber.
Valid patient-specific prescription required. Supporting clinical rationale may be requested. Compounded medications are not FDA-approved. No consumer self-ordering, no office stock, no bulk dispensing. Requests for pentadeca arginate are reviewed before any preparation is made or released. The patient-specific pharmacy route is especially important when the published PDA record is nearly absent. It keeps a marketing claim about an arginate salt from becoming a consumer product claim without prescriber documentation and pharmacist review.
Pharmacist review
For pentadeca arginate, the pharmacist review starts before any preparation is made. Valid patient-specific prescription required. Supporting clinical rationale may be requested. The pharmacist reviews ingredient status, sourcing, formulation feasibility, state requirements, patient-specific documentation, and whether dispensing is appropriate case by case.
Quality and traceability
If a pentadeca arginate preparation is approved after pharmacy review, RonanRx applies source documentation, formulation records, lot traceability, release checks, and storage controls appropriate to the actual dosage form. Research-use vial storage practices do not substitute for pharmacy-assigned storage, beyond-use dating, sterility controls when applicable, or recallable batch records.
Cold chain
If a pentadeca arginate preparation is approved after pharmacy review, RonanRx applies source documentation, formulation records, lot traceability, release checks, and storage controls appropriate to the actual dosage form. Research-use vial storage practices do not substitute for pharmacy-assigned storage, beyond-use dating, sterility controls when applicable, or recallable batch records.
FAQ
Frequently Asked Questions About Pentadeca Arginate (PDA)
Can physicians request pentadeca arginate through RonanRx?
Physicians may submit patient-specific prescription requests for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case. Compounded medications are not FDA-approved, and no consumer self-ordering, office stock, or bulk dispensing is offered.23
Is PDA the same as BPC-157?
PDA is marketed as the same 15-amino-acid sequence as BPC-157, formulated as an arginate (arginine) salt rather than the more common acetate salt. The marketing claim is that the arginate form is more stable and better absorbed 1. That claim has not been demonstrated in any peer-reviewed PubMed-indexed publication.
What does the published evidence on PDA actually show?
A PubMed search for 'pentadeca arginate' on 2026-05-11 returned zero results 1. There are no published peer-reviewed pharmacokinetic, stability, safety, or efficacy studies of PDA. Almost all PDA marketing claims rely on extrapolation from rodent studies of the parent compound BPC-157.
Does PDA have FDA approval for anything?
No. PDA has no FDA approval for any indication. There is no Prescribing Information, no USP monograph, and no FDA-approved manufactured product 2.
What about the BPC-157 research from Croatia, doesn't that support PDA?
The BPC-157 preclinical literature is broad in topic but narrow in source, most of it comes from a single research group at the University of Zagreb, in rodent injury models, without independent replication at scale. A 2025 patent-and-literature review explicitly highlighted that concentration 20211. Independent narrative and systematic reviews in 2025-2026 emphasize that human evidence remains insufficient, and PDA itself has no published research of its own 151917.
If a patient has already been using PDA from a research-peptide source, what should they do?
Discuss the exposure with a treating clinician. There is no validated PDA-specific monitoring panel, but a clinical assessment for injection-site reactions, hypersensitivity, and any unexpected systemic signs is appropriate, and the exposure should be documented in the medical record 1.
Clinician resource
Download the Pentadeca Arginate (PDA) Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[pubmed_search_pda_2026] RonanRx clinical content team. PubMed search: "pentadeca arginate" — zero results on 2026-05-11. PubMed (NCBI E-utilities). 2026. https://pubmed.ncbi.nlm.nih.gov/?term=%22pentadeca+arginate%22 (accessed 2026-05-11)
"Quoted phrase 'pentadeca arginate' returned zero indexed records as of 2026-05-11; no PDA-specific peer-reviewed publications identified."
[usp_797] United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-797 (accessed 2026-05-11)
[sikiric1999] Sikirić P, Seiwerth S, Desković S, Grabarević Z, Marović A, Rucman R, Petek M, Konjevoda P, Jadrijević S, Sosa T, Perović D, Aralica G, Turković B. New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. European Journal of Pharmacology. 1999. PMID 9920181. (accessed 2026-05-11)
[sikiric2012_colitis] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic B. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry. 2012. PMID 22300085. (accessed 2026-05-11)
[cerovecki2010] Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010. PMID 20225319. (accessed 2026-05-11)
[seiwerth2021] Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021. PMID 34267654. (accessed 2026-05-11)
[japjec2021] Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, Buljan M, Vranes H, Giljanovic A, Drmic D, Japjec M, Prtoric A, Lovric E, Batelja Vuletic L, Dobric I, Boban Blagaic A, Skrtic A, Seiwerth S, Predrag S. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021. PMID 34829776. (accessed 2026-05-11)
[staresinic2022] Staresinic M, Japjec M, Vranes H, Prtoric A, Zizek H, Krezic I, Gojkovic S, Smoday IM, Oroz K, Staresinic E, Dretar V, Yago H, Milavic M, Sikiric S, Lovric E, Batelja Vuletic L, Simeon P, Dobric I, Strbe S, Kokot A, Vlainic J, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022. PMID 36551977. (accessed 2026-05-11)
[sikiric2023_review] Sikiric P, Boban Blagaic A, Krezic I, Zizek H, Kalogjera L, Smoday IM, Vukovic V, Oroz K, Chiddenton HM, Buric S, Antunovic M, Gojkovic S, Strbe S, Skocic M, Sikiric S, Milavic M, Beketic Oreskovic L, Kokot A, Koprivanac A, Dobric I, Sever M, Staresinic M, Batelja Vuletic L, Skrtic A, Seiwerth S. From Selye's and Szabo's Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities. Pharmaceuticals (Basel). 2023. PMID 38139825. (accessed 2026-05-11)
[vukusic2024] Vukusic D, Zenko Sever A, Sever M, Drmic D, Milavic M, Sikiric S, Rasic D, Krezic I, Gojkovic S, Prtoric A, Bubalo P, Coric L, Dobric I, Boban Blagaic A, Rasic Z, Skrtic A, Seiwerth S, Sikiric P. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. Journal of Physiology and Pharmacology. 2024. PMID 38583442. (accessed 2026-05-11)
[bajramagic2024] Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, Oreskovic I, Strbe S, Loga Zec S, Hrabar J, Coric L, Prenc M, Blagaic V, Brcic K, Boban Blagaic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel). 2024. PMID 39204186. (accessed 2026-05-11)
[sikiric2024_review] Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday IM, Vukovic V, Oroz K, Coric L, Skoro M, Kavelj I, Zubcic S, Sikiric S, Beketic Oreskovic L, Oreskovic I, Blagaic V, Brcic K, Strbe S, Staresinic M, Boban Blagaic A, Skrtic A, Seiwerth S. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. 2024. PMID 38980576. (accessed 2026-05-11)
[jozwiak2025_review] Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025. PMID 40005999. (accessed 2026-05-11)
[sikiric2025_comment] Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel). 2025. PMID 41155565. (accessed 2026-05-11)
[vasireddi2025_systematic_review] Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. PMID 40756949. (accessed 2026-05-11)
[whitehouse2025_commentary] Whitehouse M. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT). Inflammopharmacology. 2025. PMID 40759852. (accessed 2026-05-11)
[mcguire2025_review] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. PMID 40789979. (accessed 2026-05-11)
[mayfield2026_primer] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine. 2026. PMID 41476424. (accessed 2026-05-11)
[mendias2026_review] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. PMID 41966639. (accessed 2026-05-11)
How to access
How to Access Pentadeca Arginate (PDA)
Physicians may submit patient-specific prescription requests for Pentadeca Arginate (PDA) for pharmacy review. Availability is determined case by case, and RonanRx is monitoring FDA's PCAC process and any subsequent agency action.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Pentadeca Arginate (PDA), sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Pentadeca Arginate (PDA).
